Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Hyaluronidase/Pembrolizumab - Merck

Drug Profile

Hyaluronidase/Pembrolizumab - Merck

Alternative Names: MK-3475/MK-5180; MK-3475A; MK-5180/MK-3475; Pembrolizumab + hyaluronidase subcutaneous - Merck; Pembrolizumab/Hyaluronidase - Merck; Pembrolizumab/MK-5180; Recombinant human hyaluronidase and pembrolizumab - Merck

Latest Information Update: 04 Dec 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Merck Sharp & Dohme
  • Class Antineoplastics; Glycoside hydrolases; Immunotherapies; Monoclonal antibodies; Polysaccharide lyases; Small molecules; Tumour-agnostic therapies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; Programmed cell death-1 receptor antagonists; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase III Non-small cell lung cancer
  • Phase II Malignant melanoma; Renal cell carcinoma; Squamous cell cancer
  • Phase I Solid tumours

Most Recent Events

  • 01 Dec 2023 Phase-II clinical trials in Malignant melanoma (Metastatic disease) in USA (SC) (NCT06099782)
  • 01 Dec 2023 Phase-II clinical trials in Non-small cell lung cancer (Metastatic disease) in USA (SC) (NCT06099782)
  • 01 Dec 2023 Phase-II clinical trials in Renal cell carcinoma (Metastatic disease) in USA (SC) (NCT06099782)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top